Sugi Predict

Sugi Predict / Compounds / SCHEMBL6674366

SCHEMBL6674366

SCHEMBL6674366

C/C(=C\[C@H](C(C)C)N(C)C(=O)[C@@H](NC(=O)[C@@H](N(C)C)C(C)(C)c1ccccc1)C(C)(C)C)C(=O)O

nearest known ligand 0.64

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
▸ TUBB1 Q9H4B7 2/20 0.64
▸ STAT6 P42226 2/20 0.35
▸ ADAM17 P78536 4/20 0.32
▸ MMP1 P03956 4/20 0.32
▸ MMP2 P08253 11/20 0.31
▸ MMP3 P08254 6/20 0.31
▸ TNF P01375 1/20 0.30
▸ MMP9 P14780 1/20 0.30
▸ MMP8 P22894 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14233968 1.00 TUBB1 (0.64) TUBB1STAT6ADAM17MMP1MMP2
SCHEMBL21018573 0.92 TUBB1 (0.61) TUBB1STAT6ADAM17MMP1MMP2
SCHEMBL13847666 0.91 TUBB1 (0.54) TUBB1STAT6ADAM17MMP1
SCHEMBL4370507 0.90 TUBB1 (0.66) TUBB1STAT6ADAM17MMP1MMP2
SCHEMBL4370500 0.90 TUBB1 (0.66) TUBB1STAT6ADAM17MMP1MMP2
SCHEMBL88817 0.89 TUBB1 (0.51) TUBB1STAT6ADAM17MMP1MMP2
SCHEMBL4369806 0.89 TUBB1 (0.65) TUBB1STAT6ADAM17MMP1MMP2
SCHEMBL4365759 0.89 TUBB1 (0.65) TUBB1STAT6ADAM17MMP1MMP2
SCHEMBL4369800 0.89 TUBB1 (0.65) TUBB1STAT6ADAM17MMP1MMP2
SCHEMBL4365752 0.89 TUBB1 (0.65) TUBB1STAT6ADAM17MMP1MMP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040121965-A1 Method of treating resistant tumors WYETH HOLDINGS CORPORATION (US) 2004-06-24 — — US claimed
WO-2004026293-A2 HEMIASTERLIN DERIVATIVES FOR TREATING RESISTANT TUMORS WYETH HOLDINGS CORPORATION (US) 2004-04-01 — — WO claimed
WO-2023077126-A1 TRANS-CYCLOOCTENE CONJUGATES TAMBO, INC. (US) 2023-05-04 — — WO disclosed
WO-2023077129-A1 TETRAZINE CONJUGATES FOR IN VIVO TARGETED DELIVERY OF A PAYLOAD TAMBO, INC. (US) 2023-05-04 — — WO disclosed
WO-2019149116-A1 METHOD FOR PREPARING CONJUGATE 四川科伦博泰生物医药股份有限公司 2019-08-08 — — WO disclosed
WO-2017089895-A1 ANTIBODY-DRUG CONJUGATES COMPRISING BRANCHED LINKERS AND METHODS RELATED THERETO LEGOCHEM BIOSCIENCES, INC. (KR) 2017-06-01 — — WO disclosed
WO-2017089890-A1 CONJUGATES COMPRISING SELF-IMMOLATIVE GROUPS AND METHODS RELATED THERETO LEGOCHEM BIOSCIENCES, INC. (KR) 2017-06-01 — — WO disclosed
WO-2017089894-A1 CONJUGATES COMPRISING PEPTIDE GROUPS AND METHODS RELATED THERETO LEGOCHEM BIOSCIENCES, INC. (KR) 2017-06-01 — — WO disclosed
US-20040121965-A1 Method of treating resistant tumors WYETH HOLDINGS CORPORATION (US) 2004-06-24 — — US disclosed
WO-2004026293-A2 HEMIASTERLIN DERIVATIVES FOR TREATING RESISTANT TUMORS WYETH HOLDINGS CORPORATION (US) 2004-04-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040121965-A1 Method of treating resistant tumors SLC11A2, VHL, REN TUBB1 199/4885STAT6 2002/4885ADAM17 1762/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.